Coverage of the 2011 Q fever vaccination campaign in the Netherlands, using retrospective population-based prevalence estimation of cardiovascular risk-conditions for chronic Q fever
| Autor: | Leslie D. Isken, Patricia E. Vermeer-de Bondt, Teske Schoffelen, Miriam C. J. M. Sturkenboom, Aura Timen, Ann M. Vanrolleghem, Marcel van Deuren |
|---|---|
| Přispěvatelé: | Medical Informatics |
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Databases Factual Population Prevalence Psychological intervention lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] lcsh:Medicine Q fever Young Adult Sex Factors SDG 3 - Good Health and Well-being Risk Factors medicine Humans Young adult education lcsh:Science Netherlands Retrospective Studies education.field_of_study Multidisciplinary Geography business.industry Incidence (epidemiology) Incidence lcsh:R Vaccination Retrospective cohort study Middle Aged medicine.disease Population Surveillance lcsh:Q Female business Q Fever Research Article |
| Zdroj: | PLoS ONE PLoS One, 10, 4 PLoS ONE, Vol 10, Iss 4, p e0123570 (2015) PLoS One (print), 10(4). Public Library of Science PLoS One, 10 |
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0123570 |
| Popis: | Contains fulltext : 154899.PDF (Publisher’s version ) (Open Access) BACKGROUND: In 2011, a unique Q fever vaccination campaign targeted people at risk for chronic Q fever in the southeast of the Netherlands. General practitioners referred patients with defined cardiovascular risk-conditions (age >15 years). Prevalence rates of those risk-conditions were lacking, standing in the way of adequate planning and coverage estimation. We aimed to obtain prevalence rates retrospectively in order to estimate coverage of the Q fever vaccination campaign. METHODS: With broad search terms for these predefined risk-conditions, we extracted patient-records from a large longitudinal general-practice research-database in the Netherlands (IPCI-database). After validation of these records, obtained prevalence rates (stratified for age and sex) extrapolated to the Q fever high-incidence area population, gave an approximation of the size of the targeted patient-group. Coverage calculation addressed people actually screened by a pre-vaccination Q fever skin test and serology (coverage) and patients referred by their general practitioners (adjusted-coverage) in the 2011 campaign. RESULTS: Our prevalence estimate of any risk-condition was 3.1% (lower-upper limits 2.9-3.3%). For heart valve defects, aorta aneurysm/prosthesis, congenital anomalies and endocarditis, prevalence was 2.4%, 0.6%, 0.4% and 0.1%, respectively. Estimated number of eligible people in the Q fever high-incidence area was 11,724 (10,965-12,532). With 1330 people screened for vaccination, coverage of the vaccination campaign was 11%. For referred people, the adjusted coverage was 18%. Coverage was lowest among the very-old and highest for people aged 50-70 years. CONCLUSION: The estimated coverage of the vaccination campaign was limited. This should be interpreted in the light of the complexity of this target-group with much co-morbidity, and of the vaccine that required invasive pre-vaccination screening. Calculation of prevalence rates of risk-conditions based on the IPCI-database was feasible. This procedure proved an efficient tool for future use, when prevalence estimates for policy, implementation or surveillance of subgroup-vaccination or other health-care interventions are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|